Mirum Pharmaceuticals, INC. (MIRM) — SEC Filings

Overview

Mirum Pharmaceuticals, INC. (MIRM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 17, 2026: On April 15, 2026, Mirum Pharmaceuticals, Inc. reported changes in beneficial ownership of securities. The filing, dated April 16, 2026, details transactions related to the company's stock.

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 3 bullish, 30 neutral. The dominant filing sentiment for Mirum Pharmaceuticals, INC. is neutral.

Filing Type Overview

Mirum Pharmaceuticals, INC. (MIRM) has filed 1 4, 1 144, 1 8-K/A, 11 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

• Mirum Pharmaceuticals Files Form 4 — 4 · Apr 17, 2026 Risk: low
  On April 15, 2026, Mirum Pharmaceuticals, Inc. reported changes in beneficial ownership of securities. The filing, dated April 16, 2026, details transactions re
• 144 Filing — 144 · Apr 15, 2026
• Mirum Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Apr 8, 2026 Risk: low
  Mirum Pharmaceuticals, Inc. filed an amendment (8-K/A) on April 8, 2026, to its previously filed report. This amendment primarily concerns Item 9.01, which rela
• Mirum Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 19, 2025 Risk: medium
  Mirum Pharmaceuticals, Inc. announced on December 18, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. The fili
• 8-K Filing — 8-K · Dec 8, 2025
• Mirum Pharmaceuticals Files 8-K — 8-K · Nov 17, 2025 Risk: medium
  Mirum Pharmaceuticals, Inc. filed an 8-K on November 17, 2025, to report other events. The filing does not contain specific details about the nature of these ev
• Mirum Swings to Profit on Robust Q3 Product Sales Growth — 10-Q · Nov 4, 2025 Risk: medium
  Mirum Pharmaceuticals, Inc. reported a significant increase in product sales, reaching $133.01 million for the three months ended September 30, 2025, up from $9
• Mirum Pharma's Q2 Revenue Jumps 66% on Strong Product Sales — 10-Q · Aug 6, 2025 Risk: medium
  Mirum Pharmaceuticals, Inc. reported product revenue of $50.0 million for the three months ended June 30, 2025, a significant increase from $30.0 million in the
• Mirum Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · May 30, 2025 Risk: low
  Mirum Pharmaceuticals, Inc. filed an 8-K on May 30, 2025, reporting on matters submitted to a vote of its security holders as of May 29, 2025. The filing detail
• Mirum Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: medium
  Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
• Mirum Pharma Executive Compensation Details Released — DEF 14A · Apr 14, 2025 Risk: low
  Mirum Pharmaceuticals, Inc. filed its DEF 14A on April 14, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing inclu
• Mirum Pharmaceuticals Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
  Mirum Pharmaceuticals, Inc. filed its 2024 10-K on February 26, 2025, detailing its financial performance and business operations for the fiscal year ending Dec
• Mirum Pharmaceuticals Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Mirum Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes informati
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Mirum Pharma Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first
• SC 13G/A Filing — SC 13G/A · Oct 22, 2024
• Mirum Pharmaceuticals Q2 2024 10-Q Filing — 10-Q · Aug 7, 2024 Risk: medium
  Mirum Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue from product sales and license and other revenue. K
• SC 13G Filing — SC 13G · Jul 10, 2024
• Mirum Pharmaceuticals Files 8-K Report — 8-K · Jun 17, 2024 Risk: low
  On June 17, 2024, Mirum Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No speci
• Mirum Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 6, 2024 Risk: low
  Mirum Pharmaceuticals, Inc. filed an 8-K on June 6, 2024, to report on matters submitted to a vote of its security holders. The filing indicates that the compan
• Mirum Pharmaceuticals Files 8-K Report — 8-K · May 31, 2024 Risk: medium
  On May 31, 2024, Mirum Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information regarding "Other Events" withou
• Mirum Pharmaceuticals, Inc. Files 10-Q for Q1 2024 — 10-Q · May 8, 2024 Risk: low
  Mirum Pharmaceuticals, Inc. (MIRM) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Mirum Pharmaceuticals, Inc. filed its 10-Q report for the period
• Mirum Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 23, 2024 Risk: low
  Mirum Pharmaceuticals, Inc. (MIRM) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Annual Meeting scheduled for June 5, 2024, in a hybrid form
• Mirum Pharmaceuticals, Inc. Files 2023 Annual Report (10-K) — 10-K · Mar 15, 2024 Risk:
  Mirum Pharmaceuticals, Inc. (MIRM) filed a Annual Report (10-K) with the SEC on March 15, 2024. Mirum Pharmaceuticals, Inc. filed its 10-K report for the fiscal
• Mirum Pharma Files 8-K on Financial Condition — 8-K · Feb 28, 2024 Risk: low
  Mirum Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates that the com
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• BlackRock Discloses 5.0% Stake in Mirum Pharmaceuticals — SC 13G · Jan 31, 2024
  BlackRock Inc., a massive investment firm, reported on January 31, 2024, that it holds a significant stake in Mirum Pharmaceuticals, Inc. As of December 31, 202
• Mirum Pharma Reports Executive Changes/Compensatory Arrangements — 8-K · Jan 16, 2024
  Mirum Pharmaceuticals, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 11, 2024. This filing indicates a change in the compan
• Mirum Pharma Files 8-K on Operations & Financial Condition — 8-K · Jan 8, 2024
  Mirum Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as Regulation FD disclosure

Risk Profile

Risk Assessment: Of MIRM's 19 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Mirum Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 4, 2025):

• Revenue: $133.01M
• Net Income: $2.90M
• EPS: $0.06
• Debt-to-Equity: 1.69
• Cash Position: $378.0M
• Operating Margin: 1.96%
• Total Assets: $785.12M
• Total Debt: $325.35M

Key Executives

• Ramasastry Saira

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like Mirum Pharmaceuticals focus on developing novel therapies for rare diseases, often requiring substantial capital for clinical trials and commercialization. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, with success often hinging on intellectual property, regulatory approvals, and effective market access.

Top Tags

8-k (4) · 10-Q (4) · pharmaceuticals (4) · sec-filing (3) · Pharmaceuticals (3) · SEC Filing (3) · corporate-governance (3) · financials (3) · Revenue Growth (2) · shareholder-vote (2)

Key Numbers

• Period of Report: 2026-04-15 — Date of reported ownership change
• Filing Date: 2026-04-16 — Date the form was officially filed
• SEC Accession Number: 0001759425-26-000021 — Unique identifier for this specific filing
• SIC Code: 2834 — Pharmaceutical Preparations industry classification
• Fiscal Year End: 1231 — Indicates the end of the company's financial reporting year
• Product sales, net (Q3 2025): $133.01M — Increased 47.3% from $90.30 million in Q3 2024
• Net income (Q3 2025): $2.90M — Swung from a net loss of $14.24 million in Q3 2024
• Total revenue (9 months ended Sep 30, 2025): $372.38M — Increased from $237.47 million in the prior year period
• Accumulated deficit (as of Sep 30, 2025): $661.8M — Indicates historical losses despite recent quarterly profit
• Unrestricted cash, cash equivalents and investments (as of Sep 30, 2025): $378.0M — Provides liquidity for at least 12 months
• Shares outstanding (as of Oct 31, 2025): 51,393,574 — Reflects common stock outstanding
• Net income per share, basic (Q3 2025): $0.06 — Positive EPS compared to -$0.30 in Q3 2024
• Stock-based compensation (9 months ended Sep 30, 2025): $52.40M — Significant non-cash expense impacting profitability
• Q2 2025 Product Revenue: $50.0M — Increased from $30.0M in Q2 2024, showing 66% growth.
• YTD 2025 Product Revenue: $95.0M — Increased from $55.0M in YTD 2024, indicating strong year-over-year growth.

Related Companies

MIR

Frequently Asked Questions